Loading
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Previous close
$1.04
+$0.05 · +5.05%
After-hours
$0.9901
−$0.0499 · -4.80%
Oct 7, 5:07 PM ET
Regular session · ET · Market data may be delayed.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Day range
Current $1.04
52-week range
Current $1.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
36
Expensive
Sentiment
50
Mixed
Risk
71
High Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanced clinical development, with ongoing Phase III trials for muscle recovery after hip fracture surgery, Phase II studies for acute respiratory distress syndrome associated with COVID-19, and Phase I/II trials for steroid-refractory Graft-versus-Host Disease. Additionally, Pluri is advancing PLX-R18, a treatment designed to aid in incomplete hematopoietic recovery following hematopoietic cell transplantation and to address acute radiation syndrome. The company rebranded to Pluri Inc. in July 2022, having previously operated as Pluristem Therapeutics Inc.
Day range
Current $1.04
52-week range
Current $1.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.02M USD | 1.34M USD | 326K USD | 287K USD | 234K USD |
| Cost of goods sold | 563K USD | 682K USD | 4K USD | 9K USD | 1.05M USD |
| Gross profit | 453K USD | 654K USD | 322K USD | 278K USD | −819K USD |
| Research and development | 15.31M USD | 12.85M USD | 12.45M USD | 15.75M USD | 24.38M USD |
| Selling, general, and administrative | 10.3M USD | 9.98M USD | 10.03M USD | 11.78M USD | 17.45M USD |
| Operating expenses | 25.39M USD | 22.83M USD | 22.48M USD | 27.52M USD | 40.77M USD |
| Interest income | 488K USD | 1.14M USD | 1.31M USD | 1.08M USD | 581K USD |
| Interest expense | −932K USD | 873K USD | 866K USD | 843K USD | 887K USD |
| Depreciation and amortization | 511K USD | 316K USD | 253K USD | 362K USD | 1.05M USD |
| Operating income | −24.94M USD | −22.18M USD | −22.16M USD | −27.25M USD | −41.59M USD |
| Net income | −23.82M USD | −22.58M USD | −20.89M USD | −28.32M USD | −41.24M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$12.00
1053.85% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 1, 2024 | 1:8 | — | — |
Stock split | Jul 25, 2019 | 1:10 | — | — |
Stock split | Nov 26, 2007 | 1:200 | — | — |
Effective Apr 1, 2024
1:8
Effective Jul 25, 2019
1:10
Effective Nov 26, 2007
1:200
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
